In recent months, many rheumatologists and rheumatology professionals have noted issues related to obtaining supplies of injectable and oral methotrexate for their patients with rheumatoid arthritis (RA). A conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), methotrexate is available as both oral tablets and as a subcutaneous injection for the treatment of RA and other autoimmune diseases.1…
